
    
      Outcome Measures:

      The primary outcome will be to measure spasticity with passive range of motion of the foot
      (pROM) by muscular extensibility and its traction reflex using goniometryIt will be assessed
      at baseline before the treatment, as well as after 3 weeks, 2 months, 3 months, after the
      washout period (3months), 3 months and 3 weeks, 5 months and 6 months, when the end the
      intervention.

      Secondary outcome includes: 1) Pain will be assessed with Visual Analog Scale (VAS) after the
      first application of each therapy. 2) Ascertain if the type of Gross Motor Functional
      Classification System (GMFCS) has an influence on the improvement of these two treatments; 3)
      Assess whether infiltration of Botulinum Toxin in other muscle groups have influence on the
      results of study; and 4) Undergo a qualitative registration to know the perception and
      experience that patient/family will have during this study, through a satisfaction
      questionnaire.
    
  